Virtu Financial LLC Invests $61,000 in Cardiol Therapeutics Inc. (NASDAQ:CRDL)

Virtu Financial LLC acquired a new stake in Cardiol Therapeutics Inc. (NASDAQ:CRDL) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 48,031 shares of the company’s stock, valued at approximately $61,000. Virtu Financial LLC owned about 0.06% of Cardiol Therapeutics at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in shares of Cardiol Therapeutics during the 3rd quarter worth about $29,000. Townsquare Capital LLC bought a new position in Cardiol Therapeutics during the third quarter worth about $27,000. Atria Investments Inc bought a new stake in shares of Cardiol Therapeutics in the fourth quarter worth about $174,000. Tejara Capital Ltd raised its position in shares of Cardiol Therapeutics by 75.9% during the fourth quarter. Tejara Capital Ltd now owns 3,115,437 shares of the company’s stock worth $3,988,000 after purchasing an additional 1,344,167 shares during the period. Finally, Lion Street Advisors LLC lifted its holdings in shares of Cardiol Therapeutics by 12.6% during the 4th quarter. Lion Street Advisors LLC now owns 307,666 shares of the company’s stock valued at $396,000 after purchasing an additional 34,385 shares in the last quarter. Institutional investors and hedge funds own 12.49% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on CRDL shares. RODMAN&RENSHAW raised shares of Cardiol Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 28th. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Cardiol Therapeutics in a research note on Monday, February 24th. Finally, Rodman & Renshaw began coverage on Cardiol Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $7.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $8.40.

Cardiol Therapeutics Trading Up 1.0 %

Shares of Cardiol Therapeutics stock opened at $0.97 on Tuesday. The stock has a market cap of $80.11 million, a P/E ratio of -2.49 and a beta of 0.95. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. Cardiol Therapeutics Inc. has a 12-month low of $0.88 and a 12-month high of $3.12. The business’s 50 day moving average is $1.21 and its 200-day moving average is $1.52.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.